U.S. markets closed

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
53.44+1.34 (+2.57%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close52.10
Open51.43
Bid30.00 x 1000
Ask54.20 x 3000
Day's Range50.47 - 57.19
52 Week Range24.15 - 57.19
Volume142,305
Avg. Volume503,990
Market Cap4.415B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Atea Pharmaceuticals (AVIR) Jumps: Stock Rises 9.5%
      Zacks

      Atea Pharmaceuticals (AVIR) Jumps: Stock Rises 9.5%

      Atea Pharmaceuticals (AVIR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

    • GlobeNewswire

      Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

      BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET. A live webcast of the presentation will be available on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.About Atea PharmaceuticalsAtea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.ContactsInvestors: Will O’Connor Stern Investor Relations 212-362-1200 will.oconnor@sternir.comMedia: Carol Guaccero 301-606-4722 contactus@ateapharma.com

    • GlobeNewswire

      Atea Pharmaceuticals Added to Russell 2000 Index

      BOSTON, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it has been added to the Russell 2000® Index, effective December 21, 2020, as part of the index's quarterly initial public offering (IPO) additions. "We are pleased to be added to the Russell 2000 Index, which will help to broaden our investor base and increase awareness of our Company's mission of discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases," said Jean-Pierre Sommadossi, Ph.D., Founder and Chief Executive Officer of Atea Pharmaceuticals. "In particular, we look forward to expanding visibility of our novel antiviral product candidates, including AT-527 for the treatment of COVID-19, and our proprietary purine nucleotide prodrug platform to the investment community."Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.For more information on the Russell 2000 Index and the Russell indexes IPO additions, please visit the "Russell U.S. Index IPO Additions" section on the FTSE Russell website.About Atea PharmaceuticalsAtea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.ContactsInvestors: Will O’Connor Stern Investor Relations 212-362-1200 will.oconnor@sternir.comMedia: Carol Guaccero 301-606-4722 contactus@ateapharma.com